| Project/Area Number |
26430133
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor biology
|
|---|
| Research Institution | National Cancer Center Japan |
|---|
Principal Investigator |
Ohki Rieko 国立研究開発法人国立がん研究センター, 研究所, 主任研究員 (70356252)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 神経内分泌腫瘍 / PHLDA3 / p53 / Akt |
|---|
| Outline of Final Research Achievements |
The purpose of this study is to clarify the mechanism of neuroendocrine tumor (NET) onset and to obtain results useful for NET treatment / diagnosis. We previosly found that the PHLDA3 gene encodes a novel Akt repressor and has been shown to function as a tumor suppressor gene in NET of lung and pancreas (Cell, Vol. 136 , p. 535-550, 2009, and PNAS, 111 (23), E2404-E2413, 2014). We believe that PHLDA 3 is a tumor suppressor gene of NET derived from various tissues, and we believe that Akt suppression by PHLDA3 plays a central role in NET suppression. Therefore, we believe that inhibitors of the Akt pathway may be effective for patients with LOH of the PHLDA3 gene. Furthermore, LOH of the PHLDA3 gene has a strong correlation with the prognosis of NET patients, and it is possible that LOH diagnosis of the PHLDA3 gene will make it possible to predict patient prognosis. By this research, we believe that we contributed to individualized medical care of NET patients.
|
